Archive for ‘Anesthesia Machine’

Page 1 of 212

Healthcare Startup Society Conference and Awards Ceremony in London

Healthcare Startup Society Conference and Awards Ceremony in London

healthcare-startup-society

 

Hosted by the UK-based Healthcare Startup Society, the conference and awards ceremony on December 17th brought together nearly 200 participants, including some big name medtech innovators and startups, along with tech experts, VCs, students, and “doctorpreneurs.” Attendees had traveled to the conference from as far as Silicon Valley, and while the December weather in London could never rival California, the fantastic venue in Kensington did boast resident flamingos!

Guest speakers covered an impressive array of medtech subjects throughout the day. The issue of funding, from both sides of the table, was examined with talks by the teams behind crowd source platformCrowdcube and surgical simulator company Touch Surgery.

The importance of a great team, and then how to go about building it, was emphasized by the co-founders of Doctify. Some of the challenges and rewards of innovation as a clinician within the healthcare sector were presented by Harry Thirkettle from the NHS Clinical Entrepreneur program. While the team behind smartphone-based digital otoscope, Cupris, explained what it takes to bring a device from an idea to the clinic.

Shafi Ahmed the "VR surgeon"

Shafi Ahmed the “VR surgeon”

Special guest Shafi Ahmed explained the motivation behind his recent performance of the world’s first VR live-streamed surgeryand the power of technology to help train thousands of surgeons worldwide at low cost and in increasingly remote areas.

The audience was challenged to think big by the Healthcare Startup Society’s founder,Alex Young, while the Linguisticator team took the idea of abstract learning and medical education to a whole new level with VR mind palaces. Bringing start-up wisdom from outside of the healthcare space, the co-founder of Propercorn spoke about ensuring that all you do is “done properly” and the importance of sharing your story with customers and users.

Morning networking session at the Healthcare Startup Society conference

Morning networking session at the Healthcare Startup Society conference

In spite of the perpetual London fog, the informal atmosphere sparked lively discussion and networking opportunities between attendees from different disciplines and continents. The conference culminated in the presentation of the Healthcare Startup Society award winners, including:

Device of the Year

SightPlus from Givevision – SightPlus is an innovative system that couples a smartphone with a VR-like headset and helps restore vision for those with sight problems. SightPlus allows users to adjust the focus, color, contrast, brightness, and magnification of the world around them—making reading, watching TV, or travelling independently possible, sometimes for the first time.

App of the Year

Echo – Echo offers a streamlined and sophisticated solution to allow patients to take control of their repeat prescriptions with their smartphone or smartwatch. A user’s medication list is stored in the app by scanning the barcodes or locating the drug in a database. And after giving the details of their NHS GP, the user’s prescription refills are automatically mailed to them when needed. The app also sends notifications reminding users when to take their medication, leaving them with one less thing to worry about.

Non-profit of the Year

Patient Innovation – Patient Innovation is based in Portugal but allows patients and caregivers around the world to connect. Users create and share solutions for health-related problems that they have developed independently or with collaborators. Founded in 2014, Patient Innovation boasts over 650 solutions from more than 40 countries, with solutions ranging from 3D-printed prosthetics to clothing and smartphones apps, all presented in step-by-step guides and how-to videos.

Entrepreneur of the Year

Stephanie Eltz and Suman Saha (Doctify) – Stephanie and Suman are the founding clinicians behind Doctify. Doctify is a user-focused database of UK private-practice health professionals that allows patients to search by specialism, location, and insurance coverage. The Doctify website then allows users to compare specialists after reading reviews from both verified patients and clinical colleagues, before booking a convenient appointment.

People’s Choice Award

Sensely – Focused on chronic conditions, Sensely offers an innovative avatar-based care solution in the form of a smartphone app and their virtual nurse, Molly (or Olivia in the UK version). Sensely allows a clinician to seamlessly monitor a patient’s personalized care plan after being discharged from hospital: a patient checks-in with their nurse avatar periodically, while the clinician monitors risk factors and adjusts clinical protocol accordingly. Clinicians are alerted if the patient does not obey the regimen and can coordinate a follow-up video-call or specialist appointment.

Start-up of the Year

Cera – Cera helps users coordinate in-home care for a variety of needs including elderly, palliative, respite, dementia, and post-discharge care. The Cera system connects users, by phone call or smartphone app, with qualified, vetted, and user-reviewed professional carers who set up a personalized care plan in as little as 24 hours, complete with 24/7 support.

Full story

Global Patient Fluid Status Monitor Device Market By Key Vendors, Market Drivers, Challenges, Share,Trends & Forecasts 2021

Global Patient Fluid Status Monitor Device Market By Key Vendors, Market Drivers, Challenges, Share,Trends & Forecasts 2021

WiseGuy-Reports82

 

“Patient fluid status monitor device generally refers to device used clinically to measures hydration in a patient, to determine whether or not the patient is dehydrated or retaining fluids. By quantifying fluid volume status, clinicians can optimize medical regimens and hydration critical in the management of heart failure patients; besides, patient fluid status monitor device can also be used in the treatment of hypertension patients and ESRD patients.

Currently, there are patient fluid status monitor device produced by two manufacturers available in the market, which include Medtronic and NMT (Noninvasive Medical Technologies). Besides, another company, Sensible Medical had launched a new type of patient fluid status monitor device called SensiVest?.”

Scope of the Report:
This report focuses on the Patient Fluid Status Monitor Device in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Noninvasive Medical Technologies
Medtronic
Sensible Medical

 

Complete Report Details @ https://www.wiseguyreports.com/reports/809448-global-patient-fluid-status-forecast-to-2021

 

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa

Market Segment by Type, covers
Invasive
Non-invasive

Market Segment by Applications, can be divided into
Heart Failure Treatment
Other Disease Treatment

 

Table of Contents

Global Patient Fluid Status Monitor Device Market by Manufacturers, Regions, Type and Application, Forecast to 2021 

1 Market Overview
1.1 Patient Fluid Status Monitor Device Introduction
1.2 Market Analysis by Type
1.2.1 Invasive
1.2.2 Non-invasive
1.2.3
1.3 Market Analysis by Applications
1.3.1 Heart Failure Treatment
1.3.2 Other Disease Treatment
1.3.3
1.4 Market Analysis by Regions
1.4.1 North America (USA, Canada and Mexico)
1.4.1.1 USA
1.4.1.2 Canada
1.4.1.3 Mexico
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany
1.4.2.2 France
1.4.2.3 UK
1.4.2.4 Russia
1.4.2.5 Italy
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China
1.4.3.2 Japan
1.4.3.3 Korea
1.4.3.4 India
1.4.3.5 Southeast Asia
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil
1.4.4.2 Egypt
1.4.4.3 Saudi Arabia
1.4.4.4 South Africa
1.4.4.5 Nigeria
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force

2 Manufacturers Profiles
2.1 Noninvasive Medical Technologies
2.1.1 Business Overview
2.1.2 Patient Fluid Status Monitor Device Type and Applications
2.1.2.1 Type 1
2.1.2.2 Type 2
2.1.3 Noninvasive Medical Technologies Patient Fluid Status Monitor Device Sales, Price, Revenue, Gross Margin and Market Share
2.2 Medtronic
2.2.1 Business Overview
2.2.2 Patient Fluid Status Monitor Device Type and Applications
2.2.2.1 Type 1
2.2.2.2 Type 2
2.2.3 Medtronic Patient Fluid Status Monitor Device Sales, Price, Revenue, Gross Margin and Market Share
2.3 Sensible Medical
2.3.1 Business Overview
2.3.2 Patient Fluid Status Monitor Device Type and Applications
2.3.2.1 Type 1
2.3.2.2 Type 2
2.3.3 Sensible Medical Patient Fluid Status Monitor Device Sales, Price, Revenue, Gross Margin and Market Share

…………

3 Global Patient Fluid Status Monitor Device Market Competition, by Manufacturer
3.1 Global Patient Fluid Status Monitor Device Sales and Market Share by Manufacturer
3.2 Global Patient Fluid Status Monitor Device Revenue and Market Share by Manufacturer
3.3 Market Concentration Rate
3.3.1 Top 3 Patient Fluid Status Monitor Device Manufacturer Market Share
3.3.2 Top 6 Patient Fluid Status Monitor Device Manufacturer Market Share
3.4 Market Competition Trend

4 Global Patient Fluid Status Monitor Device Market Analysis by Regions
4.1 Global Patient Fluid Status Monitor Device Sales, Revenue and Market Share by Regions
4.1.1 Global Patient Fluid Status Monitor Device Sales by Regions (2011-2016)
4.1.2 Global Patient Fluid Status Monitor Device Revenue by Regions (2011-2016)
4.2 North America Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
4.3 Europe Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
4.4 Asia-Pacific Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
4.5 South America Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
4.6 Middle East and Africa Patient Fluid Status Monitor Device Sales and Growth (2011-2016)

5 North America Patient Fluid Status Monitor Device by Countries
5.1 North America Patient Fluid Status Monitor Device Sales, Revenue and Market Share by Countries
5.1.1 North America Patient Fluid Status Monitor Device Sales by Countries (2011-2016)
5.1.2 North America Patient Fluid Status Monitor Device Revenue by Countries (2011-2016)
5.2 USA Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
5.3 Canada Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
5.4 Mexico Patient Fluid Status Monitor Device Sales and Growth (2011-2016)

6 Europe Patient Fluid Status Monitor Device by Countries
6.1 Europe Patient Fluid Status Monitor Device Sales, Revenue and Market Share by Countries
6.1.1 Europe Patient Fluid Status Monitor Device Sales by Countries (2011-2016)
6.1.2 Europe Patient Fluid Status Monitor Device Revenue by Countries (2011-2016)
6.2 Germany Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
6.3 UK Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
6.4 France Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
6.5 Russia Patient Fluid Status Monitor Device Sales and Growth (2011-2016)
6.6 Italy Patient Fluid Status Monitor Device Sales and Growth (2011-2016)

....Continued

 

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=809448

 

CONTACT US:

Norah Trent

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.WiseGuyReports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Full story

Lucid M1 Ultrasound Brain Damage Assessment System Cleared by FDA

Lucid M1 Ultrasound Brain Damage Assessment System Cleared by FDA

lucid_m1

 

Neural Analytics, a firm based in Los Angeles, CA, landed FDA clearance for its new Lucid M1 Transcranial Doppler Ultrasound System. It’s intended to analyze blood flow within the brain, detecting the state of blood vessels and helping to triage patients.

It’s an all-in-one battery powered system that can be neatly stored and used as necessary. It’s running Windows on a touchscreen as the interface and the analysis software within the device was licensed from UCLA.

It would seem that this would be a great tool for military hospitals, busy trauma wards, and maybe even for doctors serving on the sidelines of professional sports events.

Product page: Lucid M1…

Via: Neural Analytics…

 

lucid-system

Full story

Anatomage Virtual Autopsy Table Extends Possibilities in Anatomical Education

Anatomage Virtual Autopsy Table Extends Possibilities in Anatomical Education

Anatomage Virtual Autopsy Table Extends Possibilities in Anatomical Education

Virtual Dissection Table

Anatomage offers a unique, life-size virtual dissection table for the medical community. The Table offers an unprecedented realistic visualization of 3D anatomy and interactivity. Delivering accurate anatomic details, it is complementary for cadaver based dissection courses. For anatomy courses without cadavers, The Table offers the most realistic virtual cadaver. This cutting edge technology will help raise the standards of medical education to the next level.

Full Body Life Size

The Table offers stunning visualization of full body anatomy in Life Size. The perception is the next best thing to real patients or full body cadavers.

FullbodyAnatomage

Operating Table Experience

The form factor of the Table allows students to replicate a true operating table experience. The virtual patient is recumbent as students stand beside the Table and interact with the volume, rotating it easily to aid in anatomical spacial understanding. In addition, by incorporating physical instruments into a curriculum, the Table provides a medium for simulating operation procedures in a natural and intuitive manner.

Intuitive Touch Operations

Interactivity is intuitively at your finger tips. Turn patients, remove portions or completely change the view with the swipe of a finger. The Table offers both a very natural and very interactive experience.

Group Interaction and Teaching

The Table fosters dynamic, interactive learning environments. The full body, life-size form factor allows for easy integration into small group learning programs. Students and instructors can easily stand around the Table, view images together and collectively determine diagnoses. With the Table simulating a patient table, the similarity to traditional medical and anatomical teaching methods makes for an easy adoption into an existing course without significant changes to the curriculum or design of the classroom.

Gross Anatomy Education

The Table allows students to visualize skeletal tissues, muscles, organs and soft tissue. These various tissues and views can be customized by virtually slicing, layering, and segmenting the anatomy. This adds a new dimension of depth to the education that the students will receive. Custom annotations can be easily added to the visualizations of anatomical structures. With flexible annotation tools, institutions can create innovative programs, quizzes, and new methods of study that have only now become possible.

Unlimited Material

The Table comes with a full body gross anatomy model rendered from CT scan data. The data is fused with anatomically accurate, textured surface models for educational purposes. The Table can also open any data from CT, MRI, and ultra-sound scanners. Additionally 2D photographic images, or even full presentations, can also be displayed on the Table. The Table is immediately ready to incorporate into any curriculum and can be easily and inexpensively augmented with additional materials.

Virtual Dissection

When the luxury of actual dissections is not available, the virtual dissection with imaging data on the Table offers the next best solution. Based on true human anatomy, The Table delivers faithful details and realism. Students can cut the body, peel off soft tissue or remove an organ with their fingers. And unlike cadavers, the students can redo and undo the dissection again and again.

Procedure Based Teaching

In addition to general gross anatomy applications, users can apply the Table to specialty teaching applications as well. In the realm of pathology, specific cases can be used for teaching and examinations. In the realm of surgical procedures, the image data can be used as a three-dimensional framework on which to base the discussion. The images are 1:1 life size and actual devices and instruments can be presented with The Table to effectively illustrate patient and doctor positions and access. Whatever the specialty or application, The Table offers the potential to take the educational process to the next level.

Case Review

The life size 3D rendering displayed on The Table allows for case reviews with a complete medical team. Whether a radiologist is showing a case to a surgeon or a full team of specialists is reviewing a case together, it’s an easy and highly effective communication tool. This will open up new methods of collaboration between doctors that were never before possible.

Patient Consultations

Visual communication with patients is very effective on The Table. It can be used for case acceptance of a particular procedure or simply education and consultation. Showing the patient’s own scan in life-size and illustrating it in 3D is a much more effective and technologically impressive presentation than any other method.

Medical Device Presentations

For medical device companies, the best way to illustrate the usage, efficacy and application of the product is by using The Table along with real patient data. This will convey a very strong message to any potential customer. When placed in a trade-show, this will be the most dramatic attention grabbing tool to pull customers in and increase the time they stay at the booth and ask questions. Due to its advanced educational foundation, this provides the highest quality experience and delivers a trustworthy and effective presentation to doctors and clients.

Academic Institutes

The Table offers a unique digital anatomy teaching platform and digital anatomy offers various benefits:

No chemicals

No costly cadaver labs

No recurring purchasing costs

No facility and ventilation problems

Still, the Table offers a completely unique and effective educational tool that can be incorporated into any curriculum. The faculty and students can engage the subject with a great degree of immersion.

The Table can be a foundation or a supplement to any gross anatomy curriculum and teaching method. The faculty and students will be equally impressed with the visual realism and details of this life-sized virtual dissection table. The Table allows students to visualize skeletal tissues, muscles, organs and soft tissue. These various tissues and views can be customized by virtually slicing, layering, and segmenting the anatomy. This adds a new dimension of depth to the education that the students will receive. Whether the students have access to cadaver based dissections or model based dissections, The Table offers primary and supplemental information. Unlike a cadaver, the imaging data can be altered extensively and instantly restored and reused many times. The students will gain additional understanding of the spacial relationships of anatomy, locations of hard to identify structures, and will be able to better comprehend the relationships of multiple biological systems in the human body. With flexible annotation tools, institutions can create innovative programs, quizzes, and study methods.

Clinics and Hospitals

The Table can be used in many different ways in a hospital setting. It could be installed in the hospital lobby or consultation rooms to create an impressive center piece for patients and guests. It will set a great perception of the institution’s technological edge and levels of quality.

The Table adds a new dimension to patient education and consultation. It can be used for case acceptance of a particular procedure or simply routine education and consultation. Showing the patient’s own scan in life-size and illustrating it in 3D is a much more effective and technologically impressive presentation than any other method.

The life size 3D rendering displayed on The Table allows for case reviews with a complete medical team. Whether a radiologist is showing a case to a surgeon or a full team of specialists is reviewing a case together. The Table is an easy and highly effective communication tool, opening up new methods of collaboration between doctors.

Research Institutes

The Table offers a whole host of new research potential. This could be research directly related to the use of this new technology for academic teaching methods, patient education, case reviews, hospital team work and other similar studies where this new method of interaction could be assessed. It could also be used as a center piece for different researchers to come together and interact with data, images, presentations, and other media all at the same time.

Corporations

The Table adds a tremendous amount of prestige to any conference room. Companies can use it to impress their guests, business partners, or to win corporate relationships within their industry. When placed in a trade-show, this will be the most dramatic attention grabbing tool, pulling customers in and increasing the time they stay at the booth and ask questions. Due to its advanced educational foundation, this provides the highest quality experience and delivers a trustworthy and effective presentation to doctors and clients.

Hardware

The screen is 3960 x 1080 resolution. The LCD technology makes it very bright with high contract even under the day light and does not require to be operated in a dark room.

The optical touch interactive sensors do not require a human finger like capacitive sensors. Any stylus could be used to operate The Table, which could help to keep the surface clean if being used in anatomy lab environments.

The system is mobile. Users can move the system from room to room on rollers and they could be locked into a position. The Table is approximately 500 lbs in weight and is built to be very stable. Around a dozen people can easily stand around and comfortably interact each other and The Table at the same time.

Software

The unique anatomy study software is developed by Anatomage based on the renowned and successful Invivo5 imaging software technology. The software has unique rendering technology that allows for volume rendering, 3D mesh rendering and photographic rendering to simultaneously blend with each other in and accurate and consistent 3D space. When blended together it would be hard to distinguish which portion is volume rendering and which portion is surface rendering, thus creating a very advanced visualization that is unmatched.

3D Digital Anatomy Library

Also available for expanded utilization of the Table is a complete library collection of 100 real-life clinical scans involving hospital emergency cases, pathology cases, and scans featuring routine medical examinations where CT imaging modality is the standard.

Custom Use

The Table is not limited to the provided data set. Users can open any radiology scan data for 3D visualization. The system is based on FDA approved medical imaging software, and it is compatible with any DICOM data, such as CT or MRI data. Users can zoom, rotate and slice with the fingers just like the anatomy data.

Among the rows of equipment vendors and service providers at RSNA 2012, we found an interesting virtual autopsy table that may help change the way anatomy is taught in medical schools. Developed by Anatomage of San Jose, California, it should complement traditional dissection for understanding anatomy while getting students comfortable with looking at tomographic and volumetric images of their subject. Here’s a company rep showing off the Anatomage Table to the Medgadget audience:

Source : http://www.anatomage.com/product-TheTable.html

Full story

Rapid Rehab Smart Insole Will Train Athletes and Assist Rehab Patients

Rapid Rehab Smart Insole Will Train Athletes and Assist Rehab Patients

Rapid Rehab Smart Insole Will Train Athletes and Assist Rehab Patients

Nov. 8, 2012 — Move over Nike Plus. University of Utah (the U) professor Stacy Bamberg, of the Department of Mechanical Engineering, is developing a shoe insole that can gather comparable data to Nike’s popular line of high-tech sneakers and does more than track laps and airtime. The new insole, which Bamberg calls the Rapid Rehab system, will eventually help correct walking problems for people with artificial legs, hip replacements and broken legs.

Bamberg is developing the new smart insole through her startup company Veristride. She is currently on sabbatical to develop the product, and the company recently received a $150,000 Small Business Innovation Research grant and a $40,000 Technology Commercialization and Innovation grant from the Utah Governor’s Office of Economic Development.

“I started this research when I was a doctoral student 10 years ago, and it’s exciting to see everything finally coming together,” says Bamberg, who holds undergraduate and graduate degrees in engineering from MIT. “In the last few years, we have published several papers on this technology. We are now working hard to get our product to people who need it the most.”

The real-time Rapid Rehab system uses a custom gel insole with force sensors, accelerometers and gyroscopes to detect a person’s gait, or walking pattern. The immediate use for this technology is for amputees who would like to reduce how much they limp when using prosthetic legs. The Rapid Rehab system monitors footsteps and provides continuous feedback during every step.

The software component of the Rapid Rehab system is one if its biggest advantages. Bamberg and her colleagues created a smartphone application that wirelessly tracks data from the insole and provides a variety of instantaneous feedback. Users or physical therapists can choose from visual, audio or sensory feedback.

“This has been an incredible project to work on,” says Matthew Schmidt, a University of Utah graduate student in the Department of Mechanical Engineering who helped improve the insole’s electronic and software components. “Stacy is one of the world’s leading experts in the area of instrumented insole technology. Rapid Rehab could revolutionize the way physical therapists correct walking problems.”

Other students contributed to the project, including a team from the U’s Lassonde New Venture Development Center. These graduate students evaluated the commercial potential of the Rapid Rehab system and prepared a detailed business plan. In addition, the U’s Technology Commercialization Office provided critical support in launching Veristride and obtaining initial funding.

Several sensors are embedded in the insole of the Rapid Rehab system. The current prototype has two force-sensitive resistors for tracking pressure when the foot is on the ground. In addition, it has an inertial measurement unit, which includes an accelerometer and gyroscope for measuring foot position and angle. The device can be customized to track most types of foot movement or pressure.

Bamberg eventually wants to expand the uses for Rapid Rehab to help people who have received a hip replacement or suffered a bone fracture and need to correct their gait as they heal. Corrections are important because uneven steps, such as limping, can cause falls, osteoarthritis and other health problems. Beyond that, shoe companies like Nike might even be interested in applications for the sports world.

Bamberg and her colleagues have written two scientific publications about instrumented insole systems. One published in 2008, is based on her Ph.D. thesis and demonstrated the ability to use sensors in shoes for analyzing gait away from a motion lab. The other is in press and further demonstrates the device’s accuracy and potential for helping people with irregular walking patterns.

Rapid Rehab has several benefits over competing technologies. Unlike a gait-analysis laboratory, it is inexpensive and can be used in any real-world setting. It is much more accurate than subjective observations by a physical therapist. It also gives users more feedback and control, which can result in quicker results.

Within a few years, Bamberg hopes to be selling the Rapid Rehab system to physical therapists and their patients for around $500.

“We are on the verge of having a major impact on the lives of amputees and others who struggle with gait abnormalities,” says Bamberg. “We will be working rapidly toward commercial production. All the essential pieces are already in place. We want our system to be used by every physical therapist in the country and across the world.”

Over at the University of Utah, engineering professor Stacy Bamberg has developed a smart shoe insole to shamelessly compete with Nike’s line of high-tech shoes and running products. More importantly, though, it may help patients with prosthetic legs and people undergoing rehab to correct their gait after a hip fracture or replacement.

The device, called Rapid Rehab, consists of a custom gel insole embedded with force sensors, accelerometers, and gyroscopes to detect a person’s gait. Rapid Rehab also contains a wireless transmitter to send the data from the sensors to a custom smartphone app that tracks it and provides immediate visual, audio, or sensory feedback to the user. The current version specifically contains two force-sensitive resistors for tracking pressure when the foot is on the ground and an accelerometer and gyroscope for measuring foot movement and angle of position.

Right now, the Rapid Rehab insole is being used by amputees who want to reduce how much they limp when using a prosthetic leg. However, Bamberg hopes to expand the use to physical therapists and their patients who have received a hip replacement or suffered a bone fracture and need to correct their gait, as Rapid Rehab has shown to be less expensive than a gait-analysis lab, more accurate than subjective observations by a physical therapist, and faster at providing feedback.

We’re sure she probably wouldn’t someday mind seeing Rapid Rehab technology in a pair of Nike Airs either.

Source : http://unews.utah.edu/news_releases/utah-engineering-prof-invents-smart-insole-to-correct-walking-abnormalities/

Full story

On-X Launches Aortic Prosthetic Valve with Anatomic Sewing Ring and Chord-X ePTFE Suture

On-X Launches Aortic Prosthetic Valve with Anatomic Sewing Ring and Chord-X ePTFE Suture

On-X Launches Aortic Prosthetic Valve with Anatomic Sewing Ring and Chord-X ePTFE Suture

The On-X aortic valve with an anatomic shaped sewing ring and ePTFE suture for repair of mitral valve chordae presented at EACTS

AUSTIN, TX – October 29, 2012 – On-X® Life Technologies, Inc. (On-X LTI) announced today that it is launching two new heart valve products, the On-X® Aortic Prosthetic Valve with Anatomic Sewing Ring and an ePTFE suture Chord-X® for repair and replacement of mitral valve chordae tendeneae “chords,” at the European Association for Cardio-Thoracic Surgery (EACTS) meeting in Barcelona, Spain, on October 28-31, 2012.

On-X heart valves are made of pure On-X Pyrolytic Carbon and have an advanced design that causes less blood cell damage than traditional mechanical valves. Long-term studies, such as the Prospective Randomized On-X Valve Reduced Anticoagulation Clinical Trial (PROACT) have documented fewer morbid events in recipients of On-X valves and compelling results indicating that patients may require less anticoagulation. With the addition of the anatomic sewing ring, the valve is now easier to implant in small patients very common in southern Europe, Latin American and Asia.

“The On- X Aortic Valve with Anatomic Sewing Ring combines two very important advances in mechanical valve technology,” said Xavier Ruyra-Baliarda, M.D., FECTS, of Barcelona, and a main inventor for the anatomic sewing cuff. “Unlike previous mechanical valve sewing rings, the anatomic sewing ring matches the anatomy of the aortic annulus, thereby precluding the need for flattening of the annulus and potential related complications.”

In addition to the launch of the new products, On-X LTI hosted a reception for EACTS attendees on Sunday, October 28. During the reception, Dr. Ruyra-Baliarda presented the On-X valves advanced design features and Thierry Mesana, M.D., Ph.D., of Ottawa, Canada, provided a PROACT update.

“It is an exciting time at On-X Life Technologies,” said Clyde Baker, On-X LTI’s president. “Last week we announced the submission to the FDA/CE authorities of an application to modify the Instructions for Use (IFU) for the On-X valve to lower anticoagulation levels than the previously recommended by profession society guidelines. This week, we are launching an important new feature—the anatomic sewing cuff model—as well as entering the mitral valve repair market. We look forward to a very positive EACTS meeting.”

The On-X valve is the result of a breakthrough in medical grade carbon technology—On-X® pure pyrolytic carbon. In addition to providing a more thromboresistant surface, the comparatively high strength of pure On-X Carbon® enabled On-X LTI to make significant valve design changes that resulted in a prosthesis that acts more like a natural valve in its treatment of blood. It is well documented that the On-X valve does not produce the turbulence and blood damage commonly produced by other mechanical heart valve prostheses and, therefore, significantly reduces the potential for life-threatening blood clots.

About On-X LTI

On-X® Life Technologies, Inc. (On-X LTI) develops heart valve replacements that significantly improve the quality of life of patients. Jack Bokros, Ph.D., and his associates founded On-X LTI in 1994 to further advance prosthetic heart valve technology by capitalizing on their new form of pyrolytic carbon. The company has FDA, CE and Japanese approval for sale of the On-X® valve. On-X LTI also provides contract-manufacturing services utilizing its patented pyrolytic carbon to manufacturers of other medical products, including orthopedic joint and spine prostheses. Headquartered in Austin, Texas, On-X LTI is a privately held company. More information is located at www.onxlti.com.

On-X Life Technologies(Austin, Texas) has announced the launch of its On-X Aortic Prosthetic Valve with Anatomic Sewing Ring and the Chord-X ePTFE Suture for mtiral valve chordae tendineae repair.

The prosthetic valve is made of On-X Pyrolytic Carbon, a proprietary pure form of isotropic pyrolytic carbon that is strong and the surface of which resists clot formation. The valve features a unique “Anatomic Sewing Ring” that adapts to the anatomy of the aortic annulus rather than the reverse, hopefully leading to better overall outcome for the patient. The company also touts the low blood turbulence levels of the valve, which should reduce the chances of thrombosis and keep more cells from being mechanically damaged.

OnXLTI anatomic valve On X Launches Aortic Prosthetic Valve with Anatomic Sewing Ring and Chord X ePTFE Suture

On-X Aortic Prosthetic Valve with Anatomic Sewing Ring

The On-X valve is the result of a breakthrough in medical grade carbon technology—On-X® pure pyrolytic carbon. In addition to providing a more thromboresistant surface, the comparatively high strength of pure On-X Carbon® enabled On-X LTI to make significant valve design changes that resulted in a prosthesis that acts more like a natural valve in its treatment of blood. It is well documented that the On-X valve does not produce the turbulence and blood damage commonly produced by other mechanical heart valve prostheses and, therefore, significantly reduces the potential for life-threatening blood clots.

Source : http://www.onxlti.com/2012/10/on-x-lti-launches-innovative-heart-valve-products-at-european-meeting-in-barcelona/

Full story

Endologix Nellix Endovascular Graft for Abdominal Aortic Aneurysms

Endologix Nellix Endovascular Graft for Abdominal Aortic Aneurysms

Endologix Nellix Endovascular Graft for Abdominal Aortic Aneurysms

IRVINE, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) — Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the current version of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms (“AAA”). Nellix is an innovative new endovascular aneurysm sealing (“EVAS”) system designed to simplify endovascular procedures, treat a broader range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.

Endologix is currently implementing a few enhancements to the Nellix System intended to further optimize the device for commercialization. When complete, the Company will submit these enhancements to its Notified Body, with expectations of gaining CE Mark approval for the commercial version of the device and beginning a limited market introduction of the enhanced system in Europe by the end of the second quarter 2013.

John McDermott, President and Chief Executive Officer, said, “Nellix has the potential to treat more AAA patients and get better clinical outcomes than any other device for the endovascular repair of AAA. Receiving CE Mark for the current version of the system is an important regulatory milestone and we look forward to providing this ground-breaking technology to physicians and their patients in 2013.”

About Endologix, Inc.

Endologix, Inc. (the “Company”) develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements relating to enhancements to, further CE Mark receipt, and the commercial launch and clinical acceptance to the Nellix System, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including delays in, product research and development efforts, regulatory submissions and approvals and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and the Company’s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

IRVINE, Calif., Sept. 6, 2012 (GLOBE NEWSWIRE) — Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the current version of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms (“AAA”). Nellix is an innovative new endovascular aneurysm sealing (“EVAS”) system designed to simplify endovascular procedures, treat a broader range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.

Endologix is currently implementing a few enhancements to the Nellix System intended to further optimize the device for commercialization. When complete, the Company will submit these enhancements to its Notified Body, with expectations of gaining CE Mark approval for the commercial version of the device and beginning a limited market introduction of the enhanced system in Europe by the end of the second quarter 2013.

John McDermott, President and Chief Executive Officer, said, “Nellix has the potential to treat more AAA patients and get better clinical outcomes than any other device for the endovascular repair of AAA. Receiving CE Mark for the current version of the system is an important regulatory milestone and we look forward to providing this ground-breaking technology to physicians and their patients in 2013.”

About Endologix, Inc.

Endologix, Inc. (the “Company”) develops and manufactures minimally invasive treatments for aortic disorders. The Company’s focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix’s Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements relating to enhancements to, further CE Mark receipt, and the commercial launch and clinical acceptance to the Nellix System, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including delays in, product research and development efforts, regulatory submissions and approvals and other economic, business, competitive and regulatory factors. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2011, and the Company’s other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

Endologix (Irvine, CA) has announced that European regulators gave the go-ahead to launch the Nellix EndoVascular Aneurysm Sealing System on the continent. It is designed to virtually seal the aortic aneurysm sac to relieve any pressure on the fragile artery as blood bypasses through the device.

Though the company is glad of the current approval, it plans on submitting application for a slightly improved version of the Nellix with the hope of making it available to physicians in Europe in the 2nd quarter of next year.

Here are the requirements that were used to select patients for clinical trials of the Nellix:

Non-aneurysmal aortic neck length of ? 5mm

Non-aneurysmal aortic neck diameter of 16 to 36mm

Maximum aortic blood flow lumen diameter of ? 60mm

Common iliac artery diameter of 8 to 35mm

Some details on the clinical trials performed using the Nellix from the product page:

In initial clinical trial experience involving 34 patients outside of the United States (Krievins DK, et al., EVAR using the Nellix Sac-anchoring Endoprosthesis: Treatment of Favourable and Adverse Anatomy, EUR J Vasc Endovasc Surg (2011), doi: 10.1016/j.ejvs.2011.03.007), 100% implant success was observed. To two year follow-up, no aneurysm rupture, conversion to open surgery or stent graft migration has been observed. One secondary procedure for distal Type I endoleak has been performed (2.9% of patients). Physician feedback has been positive, particularly as it relates to ease of use and versatility to treat both standard and more challenging aneurysm anatomies.

Source : http://investor.endologix.com/releasedetail.cfm?ReleaseID=704983

Full story

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

The novel H1N1 flu pandemic in 2009 underscored weaknesses in methods widely used to diagnose the flu, from frequent false negatives to long wait times for results. Now a four-year, National Institutes of Health-funded study of 146 patients with flu-like symptoms spearheaded by Associate Professor Catherine Klapperich (BME, MSE) has validated a prototype rapid, low-cost, accurate, point-of-care device that promises a better standard of care. Once optimized and deployed in the clinic, the new device could provide clinicians with an effective tool to quickly diagnose both seasonal and pandemic strains of influenza, and thus limit the spread of infection.

The study’s research team—Klapperich, Qingqing Cao (ME PhD’11), Madhumita Mahalanabis (BME postdoctoral fellow), Jessie Chang (BME MS’10), Brendan Carey (BME’11), Christopher Hsieh (BME’11) and Ahjegannie Stanley (summer intern) from the College of Engineering; medical personnel from the Boston University Medical Center (BUMC) Emergency Department; and an infectious disease physician from Beth Israel Deaconess Medical Center (BIDMC)/ Harvard Medical School—published its findings in the March 22 online edition of PLoS ONE.

To produce a faster, cheaper, highly accurate flu diagnostic test that could be run at the point of care, the researchers miniaturized an expensive, three-hour, lab-scale diagnostic test—known as RT-PCR and now considered the gold standard in flu detection—into a single-use microfluidic chip. About the size of a standard microscope slide, the integrated chip consists of a column at the top that extracts RNA from signature proteins in the sample associated with the influenza A virus; a middle chamber that converts the RNA into DNA; and a climate-controlled lower channel used to replicate the DNA in sufficient quantities so it can be detected by an external reader.

Working with two types of nasal specimens, the researchers used the chip to produce results that matched the high accuracy and relatively fast turn-around time of the lab-scale method.

“We wanted to show that our technique was feasible on real-world samples prepared on the chip,” said Klapperich. “Making each chip single-use decreases the possibility of cross-contamination between specimens, and the chip’s small size makes it a good candidate for true point-of-care testing.”

The microfluidic chip also proved far more effective than other commonly used flu diagnostic tests including viral culture, a lab procedure requiring up to a week to produce results; rapid immunoassays, which work like pregnancy tests but were only 40 percent reliable in detecting the presence of a flu virus in this study; and direct fluorescent antigen testing (DFA), a more accurate but labor-intensive process in which medical personnel prepare and interpret samples stained with fluorescent antibodies.

“The new test represents a major improvement over viral culture in terms of turn-around time, over rapid immunoassay tests in terms of sensitivity (ability to detect the virus from minimal sample material) and over DFA and RT-PCR in terms of ease of use and portability,” Klapperich observed.

Ultimately seeking to enable clinicians to use their microfluidic chips for frontline flu virus detection, the researchers next plan to optimize their method so that it can produce results in a third less time (an hour) with chips that cost half as much to make (five dollars). In addition, they are exploring ways to develop a lower cost external reader that’s no bigger than a clinical digital thermometer.

A rapid, low cost, accurate point-of-care (POC) device to detect influenza virus is needed for effective treatment and control of both seasonal and pandemic strains. We developed a single-use microfluidic chip that integrates solid phase extraction (SPE) and molecular amplification via a reverse transcription polymerase chain reaction (RT-PCR) to amplify influenza virus type A RNA. We demonstrated the ability of the chip to amplify influenza A RNA in human nasopharyngeal aspirate (NPA) and nasopharyngeal swab (NPS) specimens collected at two clinical sites from 2008–2010. The microfluidic test was dramatically more sensitive than two currently used rapid immunoassays and had high specificity that was essentially equivalent to the rapid assays and direct fluorescent antigen (DFA) testing. We report 96% (CI 89%,99%) sensitivity and 100% (CI 95%,100%) specificity compared to conventional (bench top) RT-PCR based on the testing of n = 146 specimens (positive predictive value = 100%(CI 94%,100%) and negative predictive value = 96%(CI 88%,98%)). These results compare well with DFA performed on samples taken during the same time period (98% (CI 91%,100%) sensitivity and 96%(CI 86%,99%) specificity compared to our gold standard testing). Rapid immunoassay tests on samples taken during the enrollment period were less reliable (49%(CI 38%,61%) sensitivity and 98%(CI 98%,100%) specificity). The microfluidic test extracted and amplified influenza A RNA directly from clinical specimens with viral loads down to 103 copies/ml in 3 h or less. The new test represents a major improvement over viral culture in terms of turn around time, over rapid immunoassay tests in terms of sensitivity, and over bench top RT-PCR and DFA in terms of ease of use and portability.

Researchers from Boston University and Harvard Medical School have been testing a new microfluidic chip that performs nucleic acid extraction and reverse transcription-PCR (RT-PCR) in one device and features easily adjustable thermal and fluidic control.

The team hopes that the new technology will speed up and make more available rapid testing and identification of influenza infections.

More about the chip from Boston University’s announcement:

f84j0fv9jf New Microfluidic Chip for Low Cost, Rapid Testing of Influenza Strains

To produce a faster, cheaper, highly accurate flu diagnostic test that could be run at the point of care, the researchers miniaturized an expensive, three-hour, lab-scale diagnostic test—known as RT-PCR and now considered the gold standard in flu detection—into a single-use microfluidic chip. About the size of a standard microscope slide, the integrated chip consists of a column at the top that extracts RNA from signature proteins in the sample associated with the influenza A virus; a middle chamber that converts the RNA into DNA; and a climate-controlled lower channel used to replicate the DNA in sufficient quantities so it can be detected by an external reader.

Working with two types of nasal specimens, the researchers used the chip to produce results that matched the high accuracy and relatively fast turn-around time of the lab-scale method.

The microfluidic chip also proved far more effective than other commonly used flu diagnostic tests including viral culture, a lab procedure requiring up to a week to produce results; rapid immunoassays, which work like pregnancy tests but were only 40 percent reliable in detecting the presence of a flu virus in this study; and direct fluorescent antigen testing (DFA), a more accurate but labor-intensive process in which medical personnel prepare and interpret samples stained with fluorescent antibodies.

Source : http://www.bu.edu/phpbin/news-cms/news/?dept=666&id=59219

Full story

NDSsi Releases Dome GX 4 Megapixel Widescreen Radiology Monitor

NDSsi Releases Dome GX 4 Megapixel Widescreen Radiology Monitor

NDSsi Releases Dome GX 4 Megapixel Widescreen Radiology Monitor

New Dome® GX Series 4 Megapixel Widescreen Color Radiology Display Now Shipping from NDS Surgical Imaging

San Jose, CA, August 6, 2012 – NDS Surgical Imaging (NDSsi) is now shipping its new Dome GX4MP radiology display, a 30-inch widescreen model offering multi-modality viewing in both color and grayscale. With resolution of 2500 x 1600, the GX4MP is ideal for reading Computed Tomography (CT) scans, MRI, PET-CT, Nuclear Medicine, Digital Pathology and Ultrasound. The product is also suited for Computed Radiography (CR) & Direct Radiography (DR) images, because the GX4MP is FDA 510(k) cleared for review and analysis.

The feature set of the Dome GX4MP brings a new level of flexibility and value to the reading room, said Daniel Webster, Vice President & General Manager, Radiology Business Unit at NDSsi. We have taken the popular 4 megapixel platform and combined it with a widescreen format plus enhanced color and grayscale options. The result is a high-performance, high-versatility display without the higher price tag typically associated with other widescreen models.

The GX4MP also features Domes unique DICOM out-of-the-box capability, with factory characterization data stored in the panel and monitored by the exclusive RightLight internal photometer, allowing the display to maintain DICOM calibration for the life of the unit. In accordance with the American College of Radiology recommendations, the GX4MP display does not utilize reflective glass with protective coatings, thereby avoiding specular reflections or blurred images.

Backed by a 5-year standard warranty, the Dome GX4MP widescreen display is engineered with a fanless cooling system to help eliminate dust, excessive noise, and associated mechanical failure. Weighing only 27lbs, the lightweight design allows for easy install and maneuverability.

About NDS Surgical Imaging

Based in Silicon Valley, CA, NDS Surgical Imaging (NDSsi) is the global leader in designing and manufacturing medical imaging and informatics systems. NDSsi technology solutions have led the way in re-defining the modern surgical OR, radiology rooms, endoscopy suites and minimally invasive environments.

At the forefront of innovation in medical imaging technology, NDSsi delivers HD visualization and informatics products that enable the clinical imaging solutions of the future, and drive constant improvements in collaborative medicine. NDSsi is a privately held company with US-based R&D and manufacturing facilities, and a global presence in more than 35 countries. For more information, visit www.ndssi.com.

New Dome® GX Series 4 Megapixel Widescreen Color Radiology Display Now Shipping from NDS Surgical Imaging

San Jose, CA, August 6, 2012 – NDS Surgical Imaging (NDSsi) is now shipping its new Dome GX4MP radiology display, a 30-inch widescreen model offering multi-modality viewing in both color and grayscale. With resolution of 2500 x 1600, the GX4MP is ideal for reading Computed Tomography (CT) scans, MRI, PET-CT, Nuclear Medicine, Digital Pathology and Ultrasound. The product is also suited for Computed Radiography (CR) & Direct Radiography (DR) images, because the GX4MP is FDA 510(k) cleared for review and analysis.

The feature set of the Dome GX4MP brings a new level of flexibility and value to the reading room, said Daniel Webster, Vice President & General Manager, Radiology Business Unit at NDSsi. We have taken the popular 4 megapixel platform and combined it with a widescreen format plus enhanced color and grayscale options. The result is a high-performance, high-versatility display without the higher price tag typically associated with other widescreen models.

The GX4MP also features Domes unique DICOM out-of-the-box capability, with factory characterization data stored in the panel and monitored by the exclusive RightLight internal photometer, allowing the display to maintain DICOM calibration for the life of the unit. In accordance with the American College of Radiology recommendations, the GX4MP display does not utilize reflective glass with protective coatings, thereby avoiding specular reflections or blurred images.

Backed by a 5-year standard warranty, the Dome GX4MP widescreen display is engineered with a fanless cooling system to help eliminate dust, excessive noise, and associated mechanical failure. Weighing only 27lbs, the lightweight design allows for easy install and maneuverability.

About NDS Surgical Imaging

Based in Silicon Valley, CA, NDS Surgical Imaging (NDSsi) is the global leader in designing and manufacturing medical imaging and informatics systems. NDSsi technology solutions have led the way in re-defining the modern surgical OR, radiology rooms, endoscopy suites and minimally invasive environments.

At the forefront of innovation in medical imaging technology, NDSsi delivers HD visualization and informatics products that enable the clinical imaging solutions of the future, and drive constant improvements in collaborative medicine. NDSsi is a privately held company with US-based R&D and manufacturing facilities, and a global presence in more than 35 countries. For more information, visit www.ndssi.com.

Source : http://www.ndssi.com/press-releases/2012/12-08-06.html

Full story

Treatment in a Human Lymphoma Xenograft Model

Treatment in a Human Lymphoma Xenograft Model

Researchers from Millennium Pharmaceuticals have demonstrated significant accuracy and dynamic sensitivity of Cerenkov Luminescence Imaging (CLI) against conventional PET imaging techniques. CLI is an emerging imaging modality similar to bio-luminescence imaging which is being investigated as a more rapid, lower-cost alternative to PET for preclinical drug discovery applications. CLI captures visible protons emitted byCerenkov Radiation, the phenomenon responsible for the bluish glow often seen in nuclear reactors and the inspiration forDr. Manhattan’s Blueish Appearance.

The research, which was published in The Journal of Nuclear Medicine, demonstrated a very high correlation between CLI and PET imaging analyses of radio-pharmaceutical (F-FDG) uptake in an in vivo preclinical anti-tumor study. dr-manhattan

Cerenkov luminescence imaging (CLI) is an emerging imaging technique that combines aspects of both optical and nuclear imaging fields. The ability to fully evaluate the correlation and sensitivity of CLI to PET is critical to progress this technique further for use in high-throughput screening of pharmaceutical compounds. To achieve this milestone, it must first be established that CLI data correlate to PET data in an in vivo preclinical antitumor study. We used MLN4924, a phase 2 oncology therapeutic, which targets and inhibits the NEDD8-activating enzyme pathway involved in the ubiquitin–proteasome system. We compared the efficacious effects of MLN4924 using PET and Cerenkov luminescence image values in the same animals.

The frequency spectrum of Cherenkov radiation by a particle is given by the Frank–Tamm formula. Unlike fluorescence or emission spectrathat have characteristic spectral peaks, Cherenkov radiation is continuous. Around the visible spectrum, the relative intensity per unit frequency is approximately proportional to the frequency. That is, higher frequencies (shorter wavelengths) are more intense in Cherenkov radiation. This is why visible Cherenkov radiation is observed to be brilliant blue. In fact, most Cherenkov radiation is in the ultravioletspectrum—it is only with sufficiently accelerated charges that it even becomes visible; the sensitivity of the human eye peaks at green, and is very low in the violet portion of the spectrum.

There is a cut-off frequency above which the equation cos θ = 1 / (nβ) cannot be satisfied. Since the refractive index is a function of frequency (and hence wavelength), the intensity does not continue increasing at ever shorter wavelengths even for ultra-relativistic particles (where v/capproaches 1). At X-ray frequencies, the refractive index becomes less than unity (note that in media the phase velocity may exceed cwithout violating relativity) and hence no X-ray emission (or shorter wavelength emissions such as gamma rays) would be observed. However, X-rays can be generated at special frequencies just below those corresponding to core electronic transitions in a material, as the index of refraction is often greater than 1 just below a resonance frequency (see Kramers-Kronig relation and anomalous dispersion).

As in sonic booms and bow shocks, the angle of the shock cone is directly related to the velocity of the disruption. The Cherenkov angle is zero at the threshold velocity for the emission of Cherenkov radiation. The angle takes on a maximum as the particle speed approaches the speed of light. Hence, observed angles of incidence can be used to compute the direction and speed of a Cherenkov radiation-producing charge.

Source:http://en.wikipedia.org/wiki/Cherenkov_radiation,http://medgadget.com/2011/12/why-dr-manhattans-skin-tone-is-great-for-drug-discovery.html

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 212
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes